View Document Preview and Link Document Date: 2014-05-29 15:30:33 Open Document File Size: 12,70 KB Share Result on Facebook
City Darmstadt / RAFAEL / / Company BioMarin Pharmaceutical Inc. / Merck Serono / Merck KGaA / Genzyme / Sanofi Company / / Country Germany / / Event FDA Phase / Business Partnership / / IndustryTerm treatment of acid maltase deficiency or Pompe disease / Treatment of Pompe Disease / manufacturing know-how / treatment of germline BRCA breast cancer / treatment of Lambert Eaton Myasthenic Syndrome / treatment of hemophilia / / MedicalCondition serious diseases / lysosomal storage disorder / cardiomyopathy / hemophilia A / late-infantile neuronal ceroid lipofuscinosis / disease / respiratory failure / germline BRCA breast cancer / late-onset Pompe disease / muscle weakness / Pompe Disease Pompe disease / disorder / acid maltase deficiency / PKU / Lambert Eaton Myasthenic Syndrome / achondroplasia / respiratory muscle weakness / Batten Disease / phenylketonuria / deficiency / late onset Pompe disease / Pompe disease / / MedicalTreatment enzyme replacement therapies / intravenous infusion / / Organization Acid Maltase Deficiency Association / European Commission / / Person Lambert Eaton Myasthenic / Jean-Jacques Bienaimé / Hank Fuchs / / Position Chief Medical Officer / President / Chief Executive Officer / / Product Kuvan / Naglazyme / Aldurazyme / VIMIZIM™ (elosulfase alfa) / BMN / Firdapse® (amifampridine) / / ProvinceOrState California / / Technology alpha / pharmacokinetics / biopharmaceuticals / SAN / / URL www.BMRN.com / / SocialTag 
May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im